![Still no role for targeting PI3K pathway in mCRPC – Arun Azad](https://oncodaily.com/pub/uploads/2023/06/Arun-Azad-1-1280x1280.png)
Photo from Arun Azad/Twitter
Jun 24, 2023, 18:25
Still no role for targeting PI3K pathway in mCRPC – Arun Azad
Now online Clinical Cancer Research- Phase IB study ipatasertib plus ipatasertib in mCR prostate cancer post-NHA. No evidence of synergistic or additive antitumor activity. No clear signal of benefit in biomarker +ve populations either.
My take: Still no role for targeting PI3K pathway in mCRPC
Source: Arun Azad/Twitter